Myocardial cytoprotectors demonstrate anti-apoptotic effect on vascular endotheliocytes

Abstract

Aim. To evaluate the effects of myocardial cytoprotectors on the levels of apoptotic endotheliocytes and membranederived microparticles of endothelial origin in peripheral blood of the patients with cardiovascular disease (CVD). Material and methods. The study included CVD patients with arterial hypertension (AH) and coronary heart disease (CHD) or AH only, all of whom gave informed consent. The control group (CG) included patients with neuro-circulatory dystonia (NCD). In all participants, peripheral blood samples were taken at baseline and after 3 weeks of trimetazidine MR therapy, to assess the levels of endotheliocytes and membrane-derived microparticles. Results. Trimetazidine MR treatment resulted in significantly reduced levels of apoptotic endotheliocytes and membrane-derived microparticles in the two main groups and the CG (p<0,05). Conclusion. Trimetazidine MR could be used as pathogenetic therapy, correcting vascular wall homeostasis in CVD patients, and also as prevention of endothelial dysfunction progression in NCD patients.